These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 7942635)

  • 1. p53 expression in ovarian borderline tumors and stage I carcinomas.
    Kupryjańczyk J; Bell DA; Yandell DW; Scully RE; Thor AD
    Am J Clin Pathol; 1994 Nov; 102(5):671-6. PubMed ID: 7942635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
    Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
    J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 gene analysis of ovarian borderline tumors and stage I carcinomas.
    Kupryjanczyk J; Bell DA; Dimeo D; Beauchamp R; Thor AD; Yandell DW
    Hum Pathol; 1995 Apr; 26(4):387-92. PubMed ID: 7705816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of p53 protein and Ki-67 reactivity in ovarian neoplasms. Correlation with histopathology.
    Harlozińska A; Bar JK; Sedlaczek P; Gerber J
    Am J Clin Pathol; 1996 Mar; 105(3):334-40. PubMed ID: 8602615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma.
    Eccles DM; Brett L; Lessells A; Gruber L; Lane D; Steel CM; Leonard RC
    Br J Cancer; 1992 Jan; 65(1):40-4. PubMed ID: 1310251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors.
    Caduff RF; Svoboda-Newman SM; Ferguson AW; Johnston CM; Frank TS
    Am J Surg Pathol; 1999 Mar; 23(3):323-8. PubMed ID: 10078924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.
    Fujita M; Enomoto T; Inoue M; Tanizawa O; Ozaki M; Rice JM; Nomura T
    Jpn J Cancer Res; 1994 Dec; 85(12):1247-56. PubMed ID: 7852189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p63 expression in epithelial ovarian tumors.
    Poli Neto OB; Candido Dos Reis FJ; Zambelli Ramalho LN; Nogueira AA; de Andrade JM
    Int J Gynecol Cancer; 2006; 16(1):152-5. PubMed ID: 16445626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors.
    Ozer H; Yenicesu G; Arici S; Cetin M; Tuncer E; Cetin A
    Diagn Pathol; 2012 Sep; 7():124. PubMed ID: 22995373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [P53-status in primary ovarian carcinomas, ovarian metastases of neoplasms in other sites and benign ovarian tumors: predictive value in comparison to histopathological parameters].
    Casper F; Weikel W; Schaffrath M; Kuner RP; Hoffmann G; Pollow B; Pollow K
    Zentralbl Gynakol; 2000; 122(3):153-9. PubMed ID: 10756599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pattern of HER-2 Gene Amplification and Protein Expression in Benign, Borderline, and Malignant Ovarian Serous and Mucinous Neoplasms.
    Mohammed RAA; Makboul R; Elsers DAH; Elsaba TMAM; Thalab AMAB; Shaaban OM
    Int J Gynecol Pathol; 2017 Jan; 36(1):50-57. PubMed ID: 27309616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of heterozygosity at the RB-1 locus and pRB immunostaining in epithelial ovarian tumors: a molecular, immunohistochemical, and clinicopathologic study.
    Gras E; Pons C; Machin P; Matias-Guiu X; Prat J
    Int J Gynecol Pathol; 2001 Oct; 20(4):335-40. PubMed ID: 11603216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of p53 protein in borderline epithelial ovarian tumors: a clinicopathologic study of 39 cases.
    Darai E; Walker-Combrouze F; Mlika-Cabanne N; Feldmann G; Madelenat P; Scoazec JY
    Eur J Gynaecol Oncol; 1998; 19(2):144-9. PubMed ID: 9611054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
    BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferative activity and p53 over-expression of ovarian epithelial tumors.
    Kuwata T; Kitagawa M; Takemura T; Hirokawa K
    Gen Diagn Pathol; 1995 Oct; 141(2):131-9. PubMed ID: 8548593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression P53 protein and chromosome aberrations in benign tumors and ovarian carcinoma].
    Kamiński K; Putowski L; Oleszczuk J
    Ginekol Pol; 2003 Sep; 74(9):741-5. PubMed ID: 14674118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts.
    Nezhat F; Cohen C; Rahaman J; Gretz H; Cole P; Kalir T
    Cancer; 2002 Jun; 94(11):2935-40. PubMed ID: 12115382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identical, unique p53 mutations in a primary ovarian mucinous adenocarcinoma and a synchronous contralateral ovarian mucinous tumor of low malignant potential suggest a common clonal origin.
    Werness BA; DiCioccio RA; Piver MS
    Hum Pathol; 1997 May; 28(5):626-30. PubMed ID: 9158713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.